MOA - Pulmonary/Anaphylaxis Flashcards
Albuterol Inhaler
selective β2-adrenergic agonist that acts on β2-adrenergic receptors of intracellular adenylyl cyclase to increase cyclic AMP levels resulting in bronchial smooth muscle relaxation.
Budesonide Inhaler
anti-inflammatory with potent glucocorticoid and weak mineralocorticoid activity. It exhibits a broad range of active inhibition against multiple cell types and mediators involving allergic and nonallergic/irritant-mediated inflammation.
Budesonide/Formoterol Inhaler
an anti-inflammatory with potent glucocorticoid and weak mineralocorticoid activity. It exhibits a broad range of active inhibition against multiple cell types and mediators involving allergic and nonallergic/irritant-mediated inflammation. One component is a long-acting selective β2-adrenergic agonist that produces bronchodilation.
Epinephrine
stimulates α- and β-adrenergic receptors. Alpha agonism results in vascular smooth muscle constriction which increases BP. Beta-1 agonism will increase HR and contractility. Beta-2 agonism results in bronchial smooth muscle relaxation thus alleviating bronchospasm, wheezing, and dyspnea. This medication treats severe allergic reactions to insect stings or bites, foods, drugs, and other allergens. It also alleviates pruritus, urticaria, and angioedema.
Fluticasone Inhaler
human glucocorticoid receptor agonist that inhibits multiple cell types and mediator production or secretion involved in asthma. Glucocorticosteroids are naturally occurring and synthetic adrenocortical steroids, cause varied metabolic effects, modify the body’s immune responses to diverse stimuli, and are used primarily for their anti-inflammatory effects in disorders of many organ systems
Fluticasone/Salmeterol Inhaler
synthetic trifluorinated corticosteroid with anti-inflammatory effects. It is a human glucocorticoid receptor agonist that inhibits multiple cell types and mediator production or secretion involved in asthma and COPD. One component is a long-acting β2-adrenergic agonist, stimulates intracellular adenylyl cyclase in catalyzing the conversion of adenosine triphosphate (ATP) to cyclic-3’,5,’-adenosine monophosphate (cyclic AMP). The increased cyclic AMP levels result in the relaxation of bronchial smooth muscle and inhibition of the release of mediators of instantaneous hypersensitivity from mast cells.
Ipratropium/Albuterol Inhaler
a selective β2-adrenergic agonist that produces bronchodilation, vasodilation, uterine relaxation, skeletal muscle stimulation, peripheral vasodilation, and tachycardia; and competitive antagonist of acetylcholine at peripheral, but not central, muscarinic receptors. It appears to produce bronchodilation by inhibition of cholinergic receptors on bronchial smooth muscle.
Levalbuterol Inhaler
activation of β2-adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3’,5’-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. It relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles
Montelukast
products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils, and bind to leukotriene receptors. It binds with leukotriene receptors to inhibit physiologic actions of leukotriene.
Tiotropium Inhaler
long-acting antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1-M5. In the airways, it exhibits pharmacologic effects through inhibition of M3-receptors at the smooth muscle leading to bronchodilation; is predominantly a site-specific effect.
